Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Needham

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Upgrades

Benzinga

Why Are Accolade Shares Down Over 40% Today

Accolade Inc (NASDAQ:ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million. The company reported a wider net loss of $(34.56) million compared to $(4.73) million a year ago. EPS loss came at $(0.51)…

Benzinga

Needham Maintains Buy Rating for Teleflex: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Teleflex (NYSE:TFX) and lower its price target from $400.00 to $355.00. Shares of Teleflex are trading down 1.62% over the last 24 hours, at $290.71 per share. A move to $355.00 would account for a 22.11% increase from the current share…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

'Long Road Of Rebuilding Begins': PayPal Analysts React To Mixed Q1 Earnings Report

Shares of PayPal Holdings Inc (NASDAQ: PYPL) gained 11% on Thursday after the company reported a revenue beat but cut its 2022 guidance.

Benzinga

Teladoc Analysts React To Shocking Q1 Losses, Rising BetterHelp Costs

A brutal 12 months for Teladoc Health Inc (NYSE: TDOC) went from bad to much worse on Thursday when the stock dropped another 43% after the company reported much larger-than-expected losses in the first quarter and slashed its 2022 guidance.

Benzinga

10 Biggest Price Target Changes For Thursday

Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading.

Benzinga

Needham Maintains Buy Rating for Calix: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Calix (NYSE:CALX) and lower its price target from $73.00 to $60.00. Shares of Calix are trading up 3.28% over the last 24 hours, at $39.34 per share. A move to $60.00 would account for a 52.52% increase from the current share…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here's Why Analysts Were Impressed Post Cadence Design Systems' Q1 Performance

Cadence Design Systems, Inc (NASDAQ:CDNS) impressed analysts post Q1 beat. Baird reiterated Outperform rating on Cadence, adjudging it as a top idea. All business groups saw strength, with recurring revenues increasing 19% YoY (led by Digital and System Design) and upfront revenues rising 49% YoY. FY22 outlook raised given 1Q strength, upside in 2Q,…

Benzinga

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.

Benzinga

Coinbase And This Cold Wallet Stock Look 'Quite Discounted' Ahead Of Potential Crypto Rally

Bitcoin (CRYPTO: BTC) is down about 10% year-to-date, but several crypto-related stocks have fallen significantly further. Needham & Company's John Todaro offered an explanation for the disconnection Tuesday on CNBC's "TechCheck."

Benzinga

Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) remains on track to complete the bentracimab biologics license application (BLA) filing around mid-2022 for bleeding risks associated with using ticagrelor antiplatelet drug.

Benzinga

Here's What Made Needham Bullish On This CyberSecurity Company

Needham hosted CrowdStrike Holdings Inc (NASDAQ:CRWD) on its first in-person NDR since COVID started. It had a Buy rating with a $340 (51.6% upside) price target. CrowdSrike developed the critical elements of technology with an integrated vision of a trustworthy Cloud-Native Security platform, from the lightweight agent with the embedded Threat Graph to the…

Benzinga

Merit Medical Bullish On FY23 Operating Margin Of 18-21%, Needham Says Could Exceed

At the Annual Needham Healthcare Conference, Merit Medical Systems Inc's (NASDAQ: MMSI) management said that inflationary pressures and supply chain issues have been manageable and have not had a material impact on its results year-to-date.

Benzinga

Here's What Made Needham Bullish On Nvidia, AMD Versus Others In Semiconductor Space

Needham shifted its focus on NVIDIA Corp (NASDAQ: NVDA) and Advanced Micro Devices Inc (NASDAQ: AMD).

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Deutsche Bank Sees Netflix In Line With 2.5M Subscriber Guidance

Deutsche Bank analyst Bryan Kraft maintained his Q1 global subscriber estimate, in line with Netflix Inc's (NASDAQ:NFLX) 2.5 million guidance amid cutthroat competition and Covid resurgence. He saw net adds inching closer to 3.5 million when not accounting for Russia's 1 million base adjustment. Also Read: Needham Sees Netflix Losing Out To Amazon, Disney, Apple and…

Benzinga

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) says that licensor Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported Takecab (vonoprazan) Q4 FY21 sales of $221 million and $900 million in FY21. Phathom estimates that around 30% is from erosive esophagitis (EE), approximately 60% is from gastroesophageal reflux disease (GERD)/other, and less than 10% is…

Benzinga

Bitcoin Miami 2022 Showed An Institutional Shift, Says Analyst

Following the conclusion of the 2022 Bitcoin (CRYPTO: BTC) conference held in Miami, Florida, an analyst at Needham shared his key takeaways.

Benzinga

Needham Sees Clear View Into STAAR Surgical's Durable Double-Digit Revenue Expansion

Needham is initiating coverage on STAAR Surgical Company (NASDAQ:STAA) with a Buy rating and an $87 price target. The analysts note that FDA approval of STAA's EVO Implantable Collamer Lens (ICLs) should serve as a meaningful tailwind for revenue. The Company generates most of its revenue from outside US markets. But after the FDA approval…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Read Why Needham Is Bullish On This Pet Retailer

Needham analyst Anna Andreeva gave Petco Health And Wellness Co Inc (NASDAQ:WOOF) a Buy rating with a price target of $30.00 (45% upside). Andreeva notes Petco is becoming an omni-channel powerhouse after revamping its digital capabilities under CEO Ron Coughlin. The analyst thinks that the company’s bundled offerings model has a significant advantage over digital-only players. Petco…

Benzinga

Needham Initiates Alcon Citing 'Visible Path to Sustainable Double-Digit EPS Growth'

Needham is initiating coverage on Alcon AG (NYSE: ALC) with a Buy rating and

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2022

Upgrades

Benzinga

Medtronic's Portfolio Management Unlikely To Be A 'Magic Bullet,' Says Needham

Needham published a report that pointed to previous comments from Medtronic plc's (NYSE: MDT) management that indicate the potential for changes in the coming year, with a spinoff of a large business considered an option.

Benzinga

Here's How Analysts View Analog Devices Post Investor Day

Analog Devices Inc (NASDAQ:ADI) highlighted its strategic vision and new financial model at its investor day meet. Piper Sandler analyst Harsh Kumar reiterated an Overweight with a $210 price target (30% upside). Kumar expects the company to benefit from several secular growth drivers within the semiconductor industry. Related: Analog Devices Tops Q1 Backed By Momentum Across…

Benzinga

Analysts Continue To See Sharp Upside In SMART Global Post Q2 Results

Analysts had a mixed take on SMART Global Holdings Inc (NASDAQ:SGH) post Q2 results. Needham analyst Ravindra Gill raised the price target to $45 (89% upside) with a Buy rating following the seventh consecutive beat raise quarter. SGH remains the firm's Top Pick for 2022. SGH's commercial and government customers have already designed and contracted the…

Benzinga

Needham Halves Price Target On Shapeways Post Q4 Results

Needham analyst James Ricchiuti reduced the price target on Shapeways Holdings Inc (NYSE: SHPW) to $5 (an upside over 100%) from $10 while still keeping the Buy rating on the shares.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations